R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.66, issue.1, pp.7-30, 2016.

L. A. Torre, B. Trabert, C. E. Desantis, K. D. Miller, G. Samimi et al., Ovarian cancer statistics, 2018.

P. Colombo, M. Fabbro, C. Theillet, F. Bibeau, P. Rouanet et al., Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer, Crit Rev Oncol Hematol, vol.89, issue.2, pp.207-216, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02181361

J. Ventriglia, I. Paciolla, C. Pisano, S. C. Cecere, D. Napoli et al., Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives, Cancer Treat Rev, vol.59, pp.109-116, 2017.

G. Mittica, S. Capellero, S. Genta, C. Cagnazzo, M. Aglietta et al., Adoptive immunotherapy against ovarian cancer, J Ovarian Res, vol.9, issue.1, p.30, 2016.

A. C. Hayday, Annu Rev Immunol, vol.18, pp.975-1026, 2000.

Y. Chien, C. Meyer, and M. Bonneville, ?? T cells: first line of defense and beyond, Annu Rev Immunol, vol.32, pp.121-155, 2014.

A. Thedrez, C. Sabourin, J. Gertner, M. Devilder, A. et al., Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue, Immunol Rev, vol.215, pp.123-135, 2007.

C. Harly, Y. Guillaume, S. Nedellec, C. Peigné, H. Mönkkönen et al., Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human ?? T-cell subset, Blood, vol.120, issue.11, pp.2269-2279, 2012.

C. Harly, C. Peigné, and E. Scotet, Molecules and mechanisms implicated in the peculiar antigenic activation process of human V?9V?2 T cells, Front Immunol, vol.5, p.657, 2014.

D. Lai, F. Wang, Y. Chen, C. Wang, S. Liu et al., Human ovarian cancer stem-like cells can be efficiently killed by ?? T lymphocytes, Cancer Immunol Immunother. CII, vol.61, issue.7, pp.979-989, 2012.

V. Lavoué, F. Cabillic, O. Toutirais, A. Thedrez, B. Dessarthe et al., Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V?9V?2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy, Int J Cancer, vol.131, issue.4, pp.449-462, 2012.

U. Jarry, C. Chauvin, N. Joalland, A. Léger, S. Minault et al., Stereotaxic administrations of allogeneic human V?9V?2 T cells efficiently control the development of human glioblastoma brain tumors

-. Fournié, H. Sicard, M. Poupot, C. Bezombes, A. Blanc et al., What lessons can be learned from ?? T cell-based cancer immunotherapy trials?, Cell Mol Immunol, vol.5, issue.6, pp.35-41, 2013.

O. Helland, M. Popa, O. K. Vintermyr, A. Molven, B. T. Gjertsen et al., First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma, PLoS One, vol.9, issue.3, p.89527, 2014.

O. Loubani and D. W. Hoskin, Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression, Anticancer Res, vol.25, pp.735-741, 2005.

Y. Kato, Y. Tanaka, M. Hayashi, K. Okawa, and N. Minato, Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens, J Immunol Baltim. Md, vol.177, issue.2, pp.877-884, 1950.

S. J. Weroha, M. A. Becker, S. Enderica-gonzalez, S. C. Harrington, A. L. Oberg et al., Tumorgrafts as in vivo surrogates for women with ovarian cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, issue.5, pp.1288-1297, 2014.

J. F. Liu, S. Palakurthi, Q. Zeng, S. Zhou, E. Ivanova et al., Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, issue.5, pp.1263-1273, 2017.

J. R. Cubillos-ruiz, M. Rutkowski, and J. R. Conejo-garcia, Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes, Cell Cycle Georget Tex, vol.9, issue.2, pp.260-268, 2010.

S. Dhillon and K. A. Lyseng-williamson, Zoledronic acid : a review of its use in the management of bone metastases of malignancy, Drugs, vol.68, issue.4, pp.507-534, 2008.

J. Green and A. Lipton, Anticancer properties of zoledronic acid, Cancer Invest, vol.28, issue.9, pp.944-957, 2010.